Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí-Uria M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menéndez S, Del Barco S, Gallego O, Pineda E, López-Martos R, Hernández A, Mesia C, Esteve-Codina A, de la Iglesia N, Balañá C, Martínez-García M, Navarro P
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
Martínez-García M, Servitja Tormo S, Vilariño Quintela N, Arance Fernández A, Berrocal Jaime A, Cantos Sánchez de Ibargüen B, Del Barco Berrón S, García Campelo R, Gironés Sarrió R, Manuel Sepúlveda-Sánchez J
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Hernandez A, Muñoz-Mármol AM, Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí-Lluciá O, Martinez-García M, Mallo M, Gut M, Del Barco S, Gallego O, Dabad M, Mesia C, Bellosillo B, Domenech M, Vidal N, Aldecoa I, de la Iglesia N, Balana C
In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil MJ, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardus A, Bellosillo B, Muñoz-Mármol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma
Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Lopez-Martos R, Del Barco S, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Mármol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menéndez S, Esteve A, Bague S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, de la Iglesia N, Balana C
Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy